Dendreon marks $9.96 million from operations during November period

By Kali Hays

New York, Dec. 24 – Dendreon Corp. reported operational income of $9.96 million for November on total revenue of $21.97 million, according to a monthly operating report filed Dec. 24 with the U.S. Bankruptcy Court for the District of Delaware.

The company’s net loss for the period was $8.4 million and it held cash and cash equivalents of $78.33 million as of Nov. 30.

Dendreon is a Seattle-based biotechnology company that focuses on novel therapeutics to enhance cancer treatment options. The Chapter 11 case number is 14-12515.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.